Trexquant Investment LP Increases Stock Position in Guardant Health, Inc. (NASDAQ:GH)

Trexquant Investment LP boosted its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 4.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 474,171 shares of the company's stock after buying an additional 18,461 shares during the period. Trexquant Investment LP owned approximately 0.38% of Guardant Health worth $14,486,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Lord Abbett & CO. LLC bought a new position in shares of Guardant Health in the third quarter worth approximately $15,624,000. Guyasuta Investment Advisors Inc. bought a new position in Guardant Health in the 4th quarter valued at approximately $206,000. Geode Capital Management LLC boosted its stake in Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock valued at $64,754,000 after purchasing an additional 29,686 shares during the last quarter. Entropy Technologies LP bought a new stake in shares of Guardant Health in the 4th quarter worth $377,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Guardant Health in the fourth quarter worth $2,211,000. Hedge funds and other institutional investors own 92.60% of the company's stock.

Guardant Health Trading Down 3.4 %

Guardant Health stock traded down $1.44 during midday trading on Friday, hitting $40.58. The stock had a trading volume of 1,891,349 shares, compared to its average volume of 2,127,084. Guardant Health, Inc. has a 52-week low of $15.81 and a 52-week high of $50.89. The company has a market capitalization of $5.01 billion, a PE ratio of -11.40 and a beta of 1.45. The firm's fifty day moving average is $44.39 and its two-hundred day moving average is $34.89.

Remove Ads

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, equities research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GH has been the topic of several recent analyst reports. Raymond James reaffirmed an "outperform" rating and set a $59.00 price objective (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Canaccord Genuity Group raised their price target on shares of Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a report on Monday, February 24th. Scotiabank increased their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Monday, February 24th. Stifel Nicolaus lifted their target price on shares of Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Finally, Stephens reiterated an "overweight" rating and set a $55.00 target price on shares of Guardant Health in a research note on Wednesday, March 26th. Twenty equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $48.95.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.